PMID- 33421183
OWN - NLM
STAT- MEDLINE
DCOM- 20211206
LR  - 20211214
IS  - 1365-2710 (Electronic)
IS  - 0269-4727 (Linking)
VI  - 46
IP  - 3
DP  - 2021 Jun
TI  - Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date 
      meta-analysis of 29 randomized controlled trials.
PG  - 571-584
LID - 10.1111/jcpt.13349 [doi]
AB  - WHAT IS KNOWN AND OBJECTIVE: Poly ADP-ribose polymerase (PARP) inhibitors have 
      emerged as one of the most exciting new treatments for patients with certain 
      types of cancer. Haematologic toxicities are common adverse events (AEs) for all 
      PARP inhibitors. We conducted a meta-analysis to fully investigate the 
      haematologic toxicities of PARP inhibitors in cancer patients. STUDY DESIGN: 
      PubMed/Medline and Embase were searched for articles published till September 
      2020. The relevant randomized controlled trials (RCTs) in cancer patients treated 
      with PARP inhibitors were retrieved, and the systematic evaluation was performed. 
      RESULTS: Twenty-nine RCTs and 9247 patients were included. The current 
      meta-analysis suggests that the use of PARP inhibitors significantly increases 
      the risk of all-grade anaemia (RR, 2.32; 95% CI, 1.78-3.01; p < 0.00001), 
      neutropenia (RR, 1.69; 95% CI, 1.38-2.07; p < 0.00001) and thrombocytopenia (RR, 
      2.54; 95% CI, 1.87-3.45; p < 0.00001). The use of these agents also significantly 
      increased the risk of high-grade anaemia (RR, 3.06; 95% CI, 2.11-4.43; 
      p < 0.00001), neutropenia (RR, 1.66; 95% CI, 1.33-2.07; p < 0.00001) and 
      thrombocytopenia (RR, 2.76; 95% CI, 1.83-4.16; p < 0.00001). Anaemia was the most 
      common haematologic toxicity, and all the five included PARP inhibitors were 
      associated with a significant increased risk of anaemia. Combination treatment 
      may reduce the risk of anaemia and thrombocytopenia compared to those receiving 
      PARP inhibitor monotherapy. WHAT IS NEW AND CONCLUSION: The available data 
      suggested that the use of PARP inhibitors was associated with a significantly 
      increased risk of haematologic toxicities.
CI  - (c) 2021 John Wiley & Sons Ltd.
FAU - Wang, Chengyuan
AU  - Wang C
AD  - College of Environment and Resource, Chongqing Technology and Business 
      University, Chongqing, P.R.China.
FAU - Li, Jing
AU  - Li J
AUID- ORCID: 0000-0002-1232-3056
AD  - College of Pharmacy, Southwest Minzu University, Sichuan, P.R.China.
LA  - eng
GR  - cstc2014pt-sy0013/The project of capacity improvement of Chongqing Key Laboratory 
      of catalysis and functional organic molecules, Chongqing major scientific and 
      technological research project/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210109
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Poly(ADP-ribose) Polymerase Inhibitors)
SB  - IM
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - Hematologic Diseases/*chemically induced
MH  - Humans
MH  - Neoplasms/*drug therapy
MH  - Poly(ADP-ribose) Polymerase Inhibitors/*adverse effects/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Severity of Illness Index
OTO - NOTNLM
OT  - PARP inhibitors
OT  - cancer
OT  - haematologic toxicity
OT  - meta-analysis
OT  - systematic review
EDAT- 2021/01/10 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/01/09 17:09
PHST- 2020/12/07 00:00 [revised]
PHST- 2020/11/17 00:00 [received]
PHST- 2020/12/17 00:00 [accepted]
PHST- 2021/01/10 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/01/09 17:09 [entrez]
AID - 10.1111/jcpt.13349 [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2021 Jun;46(3):571-584. doi: 10.1111/jcpt.13349. Epub 2021 Jan 
      9.